We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab (PIRG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05235737
Recruitment Status : Not yet recruiting
First Posted : February 11, 2022
Last Update Posted : March 10, 2022
Sponsor:
Collaborator:
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Information provided by (Responsible Party):
Wojciech Kaspera, Medical University of Silesia

Tracking Information
First Submitted Date  ICMJE February 1, 2022
First Posted Date  ICMJE February 11, 2022
Last Update Posted Date March 10, 2022
Estimated Study Start Date  ICMJE March 1, 2022
Estimated Primary Completion Date June 1, 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 1, 2022)
  • Overall survival [ Time Frame: 3 years after initial tumor surgery ]
    Proportion of patients remaining alive from initial tumor resection
  • Progression-free survival [ Time Frame: 3 years after initial tumor surgery ]
    Time from initial tumor resection to the first occurrence of progression/relapse or death from any cause, whichever occurs first
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 1, 2022)		 Time-to-progression [ Time Frame: 3 years after initial tumor surgery ]
Time from initiation of study treatment to disease progression/relapse
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: February 1, 2022)		 Usability assessment of immuno-PET imaging with 89Zr-DFO-Atezolizumab for quantitative analysis of early changes in PD-L1 expression [ Time Frame: 48 hours after surgery ]
Immuno-PET scans (Standardized Uptake Values) will be correlated with the level and distribution of T cell activation markers.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
Official Title  ICMJE A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy (Stupp Protocol) in Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).
Brief Summary

To evaluate the short-term and longer-term safety, tolerability, and effectiveness of neoadjuvant and adjuvant Pembrolizumab on top of standard therapy (Stupp protocol) in patients with Glioblastoma Multiforme (GBM).

Randomized comparison of safety, tolerability, and clinical efficacy of (1) neoadjuvant and adjuvant Pembrolizumab (on top of Stupp protocol, n=12 patients), (2) neoadjuvant Pembrolizumab (on top of Stupp protocol, n=12 patients), and (3) standard of care (Stupp protocol only, n=12 patients). Immuno-PET examination will be performed before and after surgery in all patients.
Detailed Description

This is an open-label, Phase IV study of Pembrolizumab employed in neoadjuvant and adjuvant setting on top of standard therapy to evaluate the short-term and long-term safety, tolerability and efficacy in disease control in Glioblastoma Multiforme (GBM) patients. The control arm will be a group of patients treated in accordance with Standard of Care (SoC).

The study will include 3 treatment arms (up to n=12 evaluable patients per arm) and will be conducted at single site in Poland.

Patients with GBM will be randomly assigned in 1:1:1 ratio into one of 3 treatment arms:

  • Treatment arm 1 - n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) plus adjuvant Pembrolizumab (16 cycles q3w, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 BSA for 5 days in each 28-day cycle)
  • Treatment arm 2 - n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 BSA for 5 days in each 28-day cycle)
  • Treatment arm 3 - n=12 evaluable patients - standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 BSA for 5 days in each 28-day cycle) A pre-screening period will identify potential candidates for enrollment. Once qualified to the study patients will be randomized to one of the treatment arms. Then patients randomized to treatment arm 1 and 2 will receive first dose of neoadjuvant Pembrolizumab on day 4 and day 18 (200mg each). An immuno-PET scan for these arm 1 and 2 patients will be performed on day 29 and 30. Up to 72 hours after last immuno-PET scan all patients will undergo tumor resection. After surgery all patients will be treated in accordance with standard of care (Stupp protocol) with combined radio- and chemotherapy. Radiotherapy will consist of 60Gy over 6 weeks in daily fraction of 2Gy in Mo-Fri setting and parallel chemotherapy with Temozolomide of 75mg/m2 of BSA on a daily basis. After completion of radiotherapy the chemotherapy will continue for six cycles of 28 days with 150-200mg/m2 Temozolomide on days 1-5 of each cycle. In addition, patients randomized to arm 1 will receive 16 cycles of 21 days with Pembrolizumab treatment in adjuvant setting of 200mg/cycle.

During treatment period all patients will be assessed every three months and MRI will be performed in order to evaluate disease status/response.

After EOT patient's follow up period will continue for up to 3 years from initial resection with MRI assessment every 3 months.

If progression/relapse is identified, patients will undergo a tumor resection or biopsy within 48 hours thereafter.

All patients will then stay in follow up until the end of three years follow up period or death from any cause.

The evaluation of safety, tolerability, and quality-of-life (QoL) will be based on adverse event reporting criteria (Common Terminology Criteria for Adverse Events - CTCAE/WHO Classification of Diseases - ICD10), ECOG status assessment, KPS assessment, EORTC - QLQ-C30 and EORTC-QLQ-BN20 scale.

Clinical assessment will be based on Response Assessment in Neuro-Oncology (RANO). For patients treated with immunotherapy beyond onset of objective disease progression, the iRANO scale will be used within first 6 months of immunotherapy.

Due to a significant risk of identifying other pathology than GBM (i.e. metastasic tumor) in post-surgery histopathology it is anticipated that up to additional 6 patients may be recruited in order to achieve planned number of evaluable patients.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description:
Open Label
Primary Purpose: Treatment
Condition  ICMJE Newly Diagnosed Glioblastoma
Intervention  ICMJE
  • Drug: Pembrolizumab
    Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
  • Drug: Pembrolizumab
    Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
Study Arms  ICMJE
  • Active Comparator: Treatment arm 1
    n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) plus adjuvant Pembrolizumab (16 cycles q3w, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 of body surface area (BSA) daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
    Intervention: Drug: Pembrolizumab
  • Active Comparator: Treatment arm 2
    n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
    Intervention: Drug: Pembrolizumab
  • No Intervention: Treatment arm 3
    n=12 evaluable patients - standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: February 1, 2022)		 36
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 30, 2026
Estimated Primary Completion Date June 1, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  1. Signed Informed Consent Form
  2. Age ≥ 18 years
  3. Age ≤70 years
  4. Able to comply with the study protocol in the investigator's judgment
  5. Clinically and radiologically (contrast CT, full profile MRI - T1-weighted with or without contrast, T2-weighted, FLAIR, DWI, PWI, MR-spectroscopy) confirmed diagnosis of GBM, localized outside eloquent brain areas
  6. Resectable tumor
  7. Fully physically active ≥80 points in Karnofsky performance scale
  8. Life expectancy of at least 3 months

  9. Adequate organ function (confirmed within 1 weeks before enrollment):

    1. Hemoglobin ≥ 9g/dL
    2. Absolute Neutrophils Count (ANC) ≥1.5×109/L
    3. White Blood Cells (WBC) count ≥3×109/L
    4. Platelets (PTL) ≥ 100×109/L
    5. AST/ALT ≤2.5×ULN
    6. Serum creatinine (S-Cr) ≤ ULN
    7. Glomerular Filtration Rate (GFR) ≥50mL/min
    8. Albumin ≥ LLN
    9. Bilirubin ≤ 1.5 ULN (except patients with documented Gilbert's Syndrome, who must present adequate level of direct bilirubin)
    10. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN. (Elevation of INR and aPTT due to administration of anticoagulation drugs is not a contraindication for the enrollment. However, it must return to normal range prior to surgery).
  10. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use double barrier contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 120 days after the last immuno-PET imaging.
  11. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use double barrier contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 120 days after the last immuno-PET imaging.

Exclusion criteria:

Patients who meet any of the following criteria will be excluded from study entry:

  1. Any active concomitant malignancy, except:

    1. Locally treated basal or squamous cell carcinoma
    2. Cervical carcinoma in situ
    3. Breast cancer in situ
    4. Bladder cancer in situ
    5. Low grade prostate cancer (under observation with PSA level in normal range)

  2. Any previous systemic cancer treatment, including, but not limited to:

    1. Radiotherapy
    2. Brachytherapy for brain tumor
    3. Chemotherapy
    4. Carmustine wafer treatment (Gliadel®)
    5. Any immune checkpoint inhibitor therapy or any anticancer vaccination
  3. Hypersensitivity or allergy to any substance with similar action mechanism to Pembrolizumab, Atezolizumab, Temozolomide, other monoclonal antibodies or contrast agents
  4. Any active immunosuppressive systemic therapy (except corticosteroids under 12mg)
  5. Any active autoimmune disease or systemic therapy for autoimmune disease within 2 years before enrollment
  6. History of any immunodeficiency
  7. Active infection
  8. Significant cardiovascular disease, such as New York Heart Association cardiac disease ≥ Class III, myocardial infarction within 3 months, coronary artery disease, unstable arrhythmias or unstable angina
  9. Active liver disease, hepatitis, HBV or HCV infection
  10. History of tuberculosis
  11. Any mental disorder that may affect patient's participation
  12. Any drug or psychoactive substance dependence
  13. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
  14. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to study treatment initiation
  15. Major surgical procedure within 4 weeks prior to study enrollment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
  16. Any live vaccination within 30 days before enrollment
  17. Any active immunosuppressive systemic infection including history of human immunodeficiency virus (HIV) infection
  18. Body mass index (BMI) ≥ 35 kg/m2
  19. Pregnant or lactating or intending to become pregnant during the study - women who are not postmenopausal (postmenopausal defined as ≥ 12 months of non-drug-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 2 weeks prior to initiation of study treatment
  20. Any condition that the patient's physician determines to be detrimental to the patient participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events.
  21. Inability to understand the local language for use of the patient QoL instruments.
  22. Tumor other than glioblastoma grade 4 IDH-wildtype, astrocytoma grade 3 or 4 IDH-mutant identified in post-surgery histopathology.
  23. Presence of 1p19q codeletion.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Wojciech Kaspera, Md, Phd +48-32-3682551 wkaspera@sum.edu.pl
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05235737
Other Study ID Numbers  ICMJE 2019/ABM/01/00062
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Wojciech Kaspera, Medical University of Silesia
Original Responsible Party Wojciech Kaspera, Medical University of Silesia, MD, PhD
Current Study Sponsor  ICMJE Medical University of Silesia
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Investigators  ICMJE Not Provided
PRS Account Medical University of Silesia
Verification Date February 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP